These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28146670)

  • 21. [Cytotoxic T-cell immune response against melanoma antigens].
    Ayyoub M
    Ann Dermatol Venereol; 1998 Nov; 125 Suppl 2():S34-6. PubMed ID: 9922891
    [No Abstract]   [Full Text] [Related]  

  • 22. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
    J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
    Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
    Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
    [No Abstract]   [Full Text] [Related]  

  • 24. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
    Zikich D; Schachter J; Besser MJ
    Immunotherapy; 2016; 8(1):35-43. PubMed ID: 26653685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
    Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New immunotherapy for patients with neoplasms using tumor antigens recognized by T lymphocytes].
    Kawakami Y
    Nihon Naika Gakkai Zasshi; 1998 Dec; 87(12):2536-44. PubMed ID: 9922678
    [No Abstract]   [Full Text] [Related]  

  • 27. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
    González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
    Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving the efficacy and safety of engineered T cell therapy for cancer.
    Shi H; Liu L; Wang Z
    Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer. Cancer immunotherapy is more than a numbers game.
    Offringa R
    Science; 2006 Oct; 314(5796):68-9. PubMed ID: 17023641
    [No Abstract]   [Full Text] [Related]  

  • 30. Identical T-cell receptor transcripts in multiple melanoma metastases.
    Schrama D; Fuchs E; Bröcker EB; Thor Straten P; Becker JC
    Cancer Res; 2002 Oct; 62(20):5664-7. PubMed ID: 12384521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dissection of T-cell antigen specificity in human melanoma.
    Andersen RS; Thrue CA; Junker N; Lyngaa R; Donia M; Ellebæk E; Svane IM; Schumacher TN; Thor Straten P; Hadrup SR
    Cancer Res; 2012 Apr; 72(7):1642-50. PubMed ID: 22311675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy using T cell defined tumor antigens for melanoma.
    Kawakami Y
    Microbiol Immunol; 1998; 42(12):801-13. PubMed ID: 10037214
    [No Abstract]   [Full Text] [Related]  

  • 33. High-throughput discovery of cancer-targeting TCRs.
    Bunse L; Green EW; Platten M
    Methods Enzymol; 2019; 629():401-417. PubMed ID: 31727251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probing T-cell Infiltration in Tumors.
    Cancer Discov; 2017 Jan; 7(1):5-6. PubMed ID: 27927681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New aspects of human cancer immunology].
    Kikuchi K
    Nihon Seikeigeka Gakkai Zasshi; 1997 Jul; 71(7):292-303. PubMed ID: 9276876
    [No Abstract]   [Full Text] [Related]  

  • 36. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
    van Rooij N; van Buuren MM; Philips D; Velds A; Toebes M; Heemskerk B; van Dijk LJ; Behjati S; Hilkmann H; El Atmioui D; Nieuwland M; Stratton MR; Kerkhoven RM; Kesmir C; Haanen JB; Kvistborg P; Schumacher TN
    J Clin Oncol; 2013 Nov; 31(32):e439-42. PubMed ID: 24043743
    [No Abstract]   [Full Text] [Related]  

  • 37. Exome Sequencing to Predict Neoantigens in Melanoma.
    Pritchard AL; Burel JG; Neller MA; Hayward NK; Lopez JA; Fatho M; Lennerz V; Wölfel T; Schmidt CW
    Cancer Immunol Res; 2015 Sep; 3(9):992-8. PubMed ID: 26048577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-cell epitope peptide vaccines.
    Elsawa SF; Rodeberg DA; Celis E
    Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
    Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
    J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma.
    Nishizaka S; Gomi S; Harada K; Oizumi K; Itoh K; Shichijo S
    Cancer Res; 2000 Sep; 60(17):4830-7. PubMed ID: 10987294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.